GLB-002 / GluBio Therap - LARVOL DELTA

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma (ASH 2025) - P1 | "In all 13 enrolled patients with prior treatment of lenalidomide or thalidomide, theORR was 61.5% (8/13, including 5 FL1-3a, 2 LBCL, and 1 marginal zone lymphoma [MZL]). The extent and duration of IKZF1/3 degradation correlated with the dose level andexposure of GLB-002; at 1.0 mg, the maximum degradation of IKZF1/3 was nearly complete.ConclusionGLB-002 monotherapy demonstrated a manageable safety profile and promising antitumor activities inR/R NHL patients, with similar response rate observed in patients who had prior treatment with versuswithout IMiDs, supporting our therapeutic hypothesis that GLB-002, as a next-generation IKZF1/3degrader, can overcome resistance to IMiDs. Enrollment for all NHL subtypes in the expansion cohort isstill ongoing, and further updated data will be presented."

Clinical • First-in-human • P1 data • B Cell Lymphoma • Bone Marrow Transplantation • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Targeted Protein Degradation • CRBN • IKZF1 • IKZF3

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd.

New P1 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma